Abstract:4079 Background: About 30-50% colorectal cancer patients undergoing a curative resection will experience disease recurrence ultimately. Early detection of recurrence is of great significance for improving the prognosis of colorectal cancer patients. Circulating tumor DNA (ctDNA) has been suggested to be a promising biomarker for postoperative surveillance and prognosis prediction in various cancers including colorectal cancer. However, its performance in predicting early recurrence of colorectal cancer as well as appropriate testing procedures still needs large-scale prospective studies to evaluate. Methods: A total of 246 patients with stage II-III colorectal cancer and underwent curative resection from three clinical centers of China were enrolled in this multicenter prospective cohort study. Tissue samples as well as serial plasma samples before surgery, 7 days and 6 months after surgery and 3 months interval afterwards until recurrence were collected, and subjected to deep targeted-panel sequencing containing 425 cancer-related genes. ctDNA baseline genomic alterations and dynamic changes were analyzed. Its performance in predicting early recurrence was evaluated and compared with other clinical routine investigations, including serum biomarkers CEA and CA199, and CT examination. Results: The ctDNA positive rates at baseline (before surgery) and 7 days after surgery were 72.9% and 18.1% respectively. Among 199 patients with complete survival data, 18 patients were recurrent during follow up period with a median disease-free survival of 280.5 days (114-461 days). At baseline, high clinical stage (p = 0.035), and PTEN mutation (p = 0.009) were significantly associated with increased recurrent risk; while APC mutation (p = 0.04) predicted a decreased recurrent risk. Detection of ctDNA 7 days after surgery [HR: 5.9 (1.94-17.97); p = 0.0004] or any time point before clinical recurrence [HR: 6.14 (2.3-16.38); p < 0.0001] was associated with a significantly higher recurrent risk, and the HR increased accordingly with ctDNA mutation level. In multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathological risk factors. CEA status was not significantly (p > 0.4) associated with disease-free survival. A risk scoring model comprising of clinical variables and ctDNA detection after surgery was constructed and can predict 18-month recurrence with an AUC of 0.77. Conclusions: ctDNA is a promising marker of risk stratification, and early relapse detection in resected stage II/III CRC patients. Clinical trial information: NCT03312374 .

Quantitative Real-Time Rt-Pcr Detection For Survivin, Ck20 And Cea In Peripheral Blood Of Colorectal Cancer Patients

Quantitative Real-Time RT-PCR Detection for CEA, CK20 and CK19 Mrna in Peripheral Blood of Colorectal Cancer Patients.

Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.

Quantitative Detection of Disseminated Cancer Cells in Peritoneal Washes with Real-Time RT-PCR for Patients with Colorectal Carcinoma and Its Clinical Significance

Quantitative detection of CEA level in the peritoneal cavity of colorectal carcinoma patients with real-time RT-PCR and Its clinical significance

Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers

Detection of CEA Mrna and HNP1-3 in Peripheral Blood of Patients with Colorectal Cancer and Its Clinical Significance

Clinical significance of CEA and CK20 expression in exfoliated cells by fiberoptic bronchoscopy brushing

Clinical research on detecting multimarker genera in peripheral blood of patients with colorectal carcinoma and its clinical significance

Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer

Real-time quantitative PCR detection of circulating tumor cells using tag DNA mediated signal amplification strategy

Dissemination Profile of Perioperative Tumor Cells in Peripheral Blood of Colorectal Cancer Patients Detected by Multiple Marker Genes

[Detection and Clinical Significance of Circulating Tumor Cells in Patients with Colorectal Carcinoma].

Improved real-time rt-PCR assays of two colorectal cancer peripheral blood mRNA biomarkers: a pilot study.

Molecular Detection of Disseminated Tumor Cells in the Peripheral Blood of Patients with Gastric Cancer: Evaluation of Their Prognostic Significance

[Detection of CK19 and CEA mRNA expression for the diagnosis of peripheral blood micrometastases in patients with non-small cell lung cancer].

Significance of CK20 Mrna Expression in Peripheral Blood of Colorectal Cancer Patients by Real-Time Fluorescent Quantitative RT-PCR

Multipoint Quantification of Multimarker Genes in Peripheral Blood and Micrometastasis Characteristic in Peri-Operative Esophageal Cancer Patients

The rare circulating tumor microemboli as a biomarker contributes to predicting early colorectal cancer recurrences after medical treatment